Trial · NCT03499249
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Biliary Atresia (BA) Achieving Total Serum Bile Acids Less Than or Equal to 10 *U*Mol/L Within 24 Weeks of Kasai Portoenterostomy (KP) | N-Acetylcysteine Treatment | 0 | Participants | ||
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-glutamyltransferase (GGT) Fold, and Conjugated Bilirubin (Bc) Change Above Baseline at 3 Days and 7 Days After KP (During Treatment) | N-Acetylcysteine Treatment | AST 3 days after KP | 1.5 | Standard Deviation 0.5 | fold change over baseline |
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-glutamyltransferase (GGT) Fold, and Conjugated Bilirubin (Bc) Change Above Baseline at 3 Days and 7 Days After KP (During Treatment) | N-Acetylcysteine Treatment | AST 7 days after KP | 1.4 | Standard Deviation 0.4 | fold change over baseline |
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-glutamyltransferase (GGT) Fold, and Conjugated Bilirubin (Bc) Change Above Baseline at 3 Days and 7 Days After KP (During Treatment) | N-Acetylcysteine Treatment | ALT 3 days after KP | 3.3 | Standard Deviation 2.3 | fold change over baseline |
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-glutamyltransferase (GGT) Fold, and Conjugated Bilirubin (Bc) Change Above Baseline at 3 Days and 7 Days After KP (During Treatment) | N-Acetylcysteine Treatment | ALT 7 days after KP | 2.1 | Standard Deviation 0.5 | fold change over baseline |
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-glutamyltransferase (GGT) Fold, and Conjugated Bilirubin (Bc) Change Above Baseline at 3 Days and 7 Days After KP (During Treatment) | N-Acetylcysteine Treatment | GGT 3 days after KP | 0.9 | Standard Deviation 0.3 | fold change over baseline |
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-glutamyltransferase (GGT) Fold, and Conjugated Bilirubin (Bc) Change Above Baseline at 3 Days and 7 Days After KP (During Treatment) | N-Acetylcysteine Treatment | GGT 7 days after KP | 1.7 | Standard Deviation 0.9 | fold change over baseline |
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-glutamyltransferase (GGT) Fold, and Conjugated Bilirubin (Bc) Change Above Baseline at 3 Days and 7 Days After KP (During Treatment) | N-Acetylcysteine Treatment | Bc 3 days after KP | 1.3 | Standard Deviation 0.4 | fold change over baseline |
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-glutamyltransferase (GGT) Fold, and Conjugated Bilirubin (Bc) Change Above Baseline at 3 Days and 7 Days After KP (During Treatment) | N-Acetylcysteine Treatment | Bc 7 days after KP | 1.3 | Standard Deviation 0.4 | fold change over baseline |
| Number of Patients Experiencing Sentinel Events in the First 2 Years of Life | N-Acetylcysteine Treatment | NG feeds or TPN initiation | 4 | Participants | |
| Number of Patients Experiencing Sentinel Events in the First 2 Years of Life | N-Acetylcysteine Treatment | Splenomegaly | 7 | Participants | |
| Number of Patients Experiencing Sentinel Events in the First 2 Years of Life | N-Acetylcysteine Treatment | Thrombocytopenia | 5 | Participants | |
| Number of Patients Experiencing Sentinel Events in the First 2 Years of Life | N-Acetylcysteine Treatment | Ascites | 4 | Participants | |
| Number of Patients Experiencing Sentinel Events in the First 2 Years of Life | N-Acetylcysteine Treatment | GI bleed | 0 | Participants | |
| Number of Patients Experiencing Sentinel Events in the First 2 Years of Life | N-Acetylcysteine Treatment | Portal hypertension | 5 | Participants | |
| Number of Patients Experiencing Sentinel Events in the First 2 Years of Life | N-Acetylcysteine Treatment | Liver transplant or death | 4 | Participants | |
| Number of Patients With Adverse Events Possibly Related to NAC, Including Rash, Urticaria, Pruritus, Tachycardia, Hypotension, Vomiting, Edema, Anaphylaxis, and Intravenous Line Issues | N-Acetylcysteine Treatment | Tachycardia | 1 | Participants | |
| Number of Patients With Adverse Events Possibly Related to NAC, Including Rash, Urticaria, Pruritus, Tachycardia, Hypotension, Vomiting, Edema, Anaphylaxis, and Intravenous Line Issues | N-Acetylcysteine Treatment | Other | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03499249/results